# Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

> **NCT00343720** · PHASE2 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.**

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** VELCADE
- **DRUG:** Alimta

## Key facts

- **NCT ID:** NCT00343720
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** 2007-10
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2008-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00343720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00343720, "Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00343720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*